Will the FDA approve MDMA for PTSD?

Health & MedicineOne-Off5m

KalshiVerificar disponibilidadeKYC obrigatório2% de taxaDados de resolução verificadosCalibração aproximada

Probabilidade implícita atual

Before Jan 1, 2031 56%

Líder entre 6 opções

Qualidade do mercado

40 / 100

Baixa qualidade

Volume 24h

0 €

Liquidez

1,3 mil €

Baixa liquidez

Compra / Venda

11.0% / 16.0%

Spread

5.0 pt

Spread moderado

Dados do mercado

Atualizado há 14 minutos

14/05/26, 2:001/01/27, 4:59

Tendências

Resultado24hProbabilidade

Apenas fundos simulados, sem dinheiro realIsto não é aconselhamento financeiro

Resultado escolhido

Before Jan 1, 202710%

Aposta (USDT)

Regras

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals:

Tendência de volume

2 de jul.10d de dados27 de jul.

Mercados Relacionados

Will the FDA approve camizestrant for advanced breast cancer?

47 €

Before Oct 1, 2026: 37%

KALSHI

Hantavirus pandemic in 2026?

97,7 mil €

Sim: 3%

POLYMARKET

# of views of MrBeast video day 3?

6,5 mil €

26-27M: 73%

POLYMARKET

New pandemic in 2026?

5,2 mil €

Sim: 9%

POLYMARKET

Measles cases in 2026?

Pandemic in 2026?

Ativos nestes tópicos

BitcoinBTC$63,470.17-3.14%

EthereumETH$1,881.04-4.34%

SolanaSOL$73.33-4.43%

DogecoinDOGE$0.07-4.29%

XRPXRP$1.06-4.93%

BNBBNB$564.81-1.73%

Notícias Relacionadas

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regras

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals:

Will the FDA approve MDMA for PTSD?

Health & MedicineOne-Off5m

KalshiVerificar disponibilidadeKYC obrigatório2% de taxaDados de resolução verificadosCalibração aproximada

Probabilidade implícita atual

Before Jan 1, 2031 56%

Líder entre 6 opções

Qualidade do mercado

40 / 100

Baixa qualidade

Volume 24h

0 €

Liquidez

1,3 mil €

Baixa liquidez

Compra / Venda

11.0% / 16.0%

Spread

5.0 pt

Spread moderado

Dados do mercado

Atualizado há 14 minutos

14/05/26, 2:001/01/27, 4:59

Tendências

Resultado24hProbabilidade

Apenas fundos simulados, sem dinheiro realIsto não é aconselhamento financeiro

Resultado escolhido

Before Jan 1, 202710%

Aposta (USDT)

Regras

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals:

Tendência de volume

2 de jul.10d de dados27 de jul.

Mercados Relacionados

Will the FDA approve camizestrant for advanced breast cancer?

47 €

Before Oct 1, 2026: 37%

KALSHI

Hantavirus pandemic in 2026?

97,7 mil €

Sim: 3%

POLYMARKET

# of views of MrBeast video day 3?

6,5 mil €

26-27M: 73%

POLYMARKET

New pandemic in 2026?

5,2 mil €

Sim: 9%

POLYMARKET

Measles cases in 2026?

Pandemic in 2026?

Ativos nestes tópicos

BitcoinBTC$63,470.17-3.14%

EthereumETH$1,881.04-4.34%

SolanaSOL$73.33-4.43%

DogecoinDOGE$0.07-4.29%

XRPXRP$1.06-4.93%

BNBBNB$564.81-1.73%

Notícias Relacionadas

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regras

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals: